Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3443)	6/29/2017 4:30:12 PM
From: Miljenko Zuanic	1 Recommendation Recommended By scaram(o)uche Respond to of 3661

<After a huge run into the high $20s, CARA reports somewhat mixed P2 oral OA results.> I think that trial failed, 39% and 35% reduction is misleading! What is placebo respond?

To: tuck who wrote (3443)	7/4/2017 9:59:49 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3661

As you probably know, I have been now retired for 17 years, and have not been posting much in SI.<g> CARA looked overbought at the time of your recent post, with its RSI above the 70 level.<g> Will see if the recent double bottom at the 15.25 level will provide enough support. <g> https://stockcharts.com/c-sc/sc?s=CARA&p=D&b=5&g=0&i=t37199557006&r=1499219341797 But It has been a good performer since the uptrend started last Fall.<g> http://elite.finviz.com/chart.ashx?t=CARA&ty=c&ta=0&p=w&s=l RAGL Bernard